Innovation Pharmaceuticals Inc (IPIX)

[frenchbroad]

"The global antibiotic resistance market size was valued at USD 7.81 billion in 2017 and is estimated to reach USD 12.07 billion by 2025, registering a CAGR of 5.6% during the forecast period.
https://www.abnewswire.com/pressreleases/antibiotic-resistance-market-to-reach-1207-billion-by-2025-due-to-high-burden-of-antibioticresistant-infections-and-emergence-of-multidrug-resistant-pathogens-grand-view-research-inc_601814.html

High burden of antibiotic-resistant infections and emergence of multi-drug resistant pathogens have been augmenting the market. Pharmaceutical companies, such as GlaxoSmithKline, Johnson & Johnson, Novartis, and Sanofi, are at the forefront of the global pharmaceutical industry but are less actively involved in clinical development of antibiotics.

Among gram-positive infections, MRSA accounted for the highest market share, being the primary causative pathogen for growing ABSSSI burden across the globe.
The ABSSSI segment is projected to command a sizeable share in the antibiotic resistance market throughout the forecast period.

Large pharmaceutical companies are acquiring smaller entrants with novel antibiotics. The trend is expected to shape the future of the market.

Manufacturers seek the Qualified Infectious Disease Product (QIDP) designation, which expedites the clinical review process and extends exclusivity period for new generation antibiotics of strong therapeutic value. The QIDP designation was introduced under the Generating Antibiotic Incentives Now (GAIN) Act, passed in 2012 as an extension to the U.S. Food and Drug Administration Safety and Innovation Act. The legislation aims to promote the development of new therapies for growing burden and severity of antibiotic-resistant infections."
https://www.biospace.com/article/releases/cellceutix-antibiotic-brilacidin-receives-qidp-designation-from-fda-/